R
R Andrew Moore
Researcher at University of Oxford
Publications - 270
Citations - 27083
R Andrew Moore is an academic researcher from University of Oxford. The author has contributed to research in topics: Placebo & Analgesic. The author has an hindex of 87, co-authored 254 publications receiving 24209 citations. Previous affiliations of R Andrew Moore include Churchill Hospital & John Radcliffe Hospital.
Papers
More filters
Journal ArticleDOI
The visual analogue pain intensity scale: what is moderate pain in millimetres?
TL;DR: The results indicate that if a patient records a baseline VAS score in excess of 30 mm they would probably have recorded at least moderate pain on a 4‐point categorical scale.
Journal ArticleDOI
Opioids in chronic non-cancer pain: systematic review of efficacy and safety
TL;DR: The short‐term efficacy of opioids was good in both neuropathic and musculoskeletal pain conditions, however, only a minority of patients in these studies went on to long‐term management with opioids, and conclusions concerning problems such as tolerance and addiction are not allowed.
Journal ArticleDOI
Physical activity and exercise for chronic pain in adults: an overview of Cochrane Reviews.
TL;DR: The quality of evidence was low due to participant numbers, length of intervention and follow‐up, and the evidence for any adverse effects or harm associated with physical activity and exercise interventions, though even these statistically significant results had only small‐to‐moderate effect sizes.
Journal ArticleDOI
Pregabalin for acute and chronic pain in adults
TL;DR: Efficacy was demonstrated for dichotomous outcomes equating to moderate or substantial pain relief, alongside lower rates for lack of efficacy discontinuations with increasing dose, in patients with postherpetic neuralgia and painful diabetic neuropathy.
Journal ArticleDOI
Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review.
Martin R. Tramèr,Dawn Carroll,Fiona Campbell,D John M Reynolds,R Andrew Moore,Henry J McQuay +5 more
TL;DR: The cannabinoids tested in these trials may be useful as mood enhancing adjuvants for controlling chemotherapy related sickness and potentially serious adverse effects, even when taken short term orally or intramuscularly are likely to limit their widespread use.